Navigation Links
Pipeline for New Obesity Therapies is Focus of New Report
Date:1/7/2008

SCOTTSDALE, Ariz., Jan. 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published "Thought Leader Insight & Analysis: Obesity," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for obesity therapies.

By many measures, obesity in the Western World is reaching epidemic proportions. Unlike diabetes and cardiovascular disease, however, the medical justification for treating obesity is not directly tied to hard outcomes, and the pharmacoeconomics do not yet motivate third-party payers to broadly reimburse for pharmacotherapies.

Against this backdrop, seven internationally-recognized obesity experts comment on centrally acting, peripheral and non-systemic approaches to weight reduction, including:

-- Rimonabant, comparing next-generation CB-1 antagonists and inverse

agonists in terms of efficacy and propensity to cause depression and

other psychiatric disorders,

-- Other centrally acting agents, alone and in combination,

-- The pure peripheral drugs, using exenatide as the base for comparison

and positioning other GLP-1 agonists against its weaknesses,

-- Leptin, PYY, mitochondrial metabolism and other approaches to

"inefficient caloric consumption",

-- And non-systemic mechanisms, including follow up approaches after

orlistat, and novel approaches such as SGLT inhibition.

Key drugs discussed in this report include: Acomplia (rimonabant; Sanofi-Aventis), taranabant (MK-0364; Merck), CP-945598 (Pfizer), SLV 319 (BMS-646256; Solvay / BMS), rosonabant (E-6776; Esteve), AVE-1625 (Sanofi-Aventis), LH-21 (Instituto de Quimica Medica), Qnexa (phentermine / topiramate; Vivus), Contrave (bupropion / naltrexone; Orexigen), Empatic (bupropion SR + zonisamide SR; Orexigen), Meridia (sibutramine; Abbott), lorcaserin (APD356; Arena), Byetta (exenatide; Amylin/Lilly), exenatide LAR (Lilly/Amylin/Alkermes), exenatide + recombinant leptin (r-metHuLeptin; Amylin/Amgen), Symlin (pramlintide; Amylin), pramlintide + AC162352 (PYY 3-36; Amylin), liraglutide (NN2211; Novo Nordisk), albiglutide (GSK / Human Genome Science), PC-DAC:Exendin-4 (ConjuChem), Boc5 (SH-7871; UC Riverside / Chinese Academy of Science); Substituted quinoxalines (Novo Nordisk/ Pfizer), PYY 3-36 (Nastech), CYT009-GhrQb (Cytos), Xenical / alli (orlistat; Roche / GSK), cetilistat (Alizyme/ Takeda), SGLT inhibitors.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
2. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
3. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. China Holdings, Inc. Announces Its 3rd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 150 MW in Biomass Energy Pipeline
6. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
7. Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Councils Ninth Annual MASS Opportunities Investment Conference
8. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
9. Clinical studies in the pipeline: the therapies of tomorrow in trials today
10. Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
11. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... CALNOC, ... FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – ... the chairman and CEO of the Virginia Mason Health System in Seattle since 2000. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that ... of CM-AT in children aged 3-8 with Autism, is now enrolling at three new ... children across the United States. , “There are currently no approved drugs that ...
(Date:2/23/2017)... ... ... Thomas Vas-Don suffered from severe injury due to an ... successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” (published by ... massage, anatomy , trigger points and referral pain patterns . , In ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
(Date:2/22/2017)... Raton, FL (PRWEB) , ... February 22, 2017 , ... ... primarily from deer antler velvet, announced its products are coming soon to Amazon.com, the ... Clint and Shelley Thomson as a means to develop an effective natural treatment for ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... February 23, 2017 Persistence ... the global market for intraoperative imaging, excerpts from ... at US$ 513.9 million. According to the report, ... on the grounds of increasing adoption of minimally-invasive ... of diagnostic imaging for neurosurgeries. The world,s leading ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
Breaking Medicine Technology: